TP53 and central nervous system neoplasm: In fact, the most frequent molecular alterations identified in glioma and glioblastoma patients (CDKN2A/2B, PTEN, TP53, TERT, PIK3CA/B and EGFR alterations) have no clinically active drugs for treatment of CNS tumors.